| Document |
Document Title |
|
WO/2004/099163A1 |
Two methods are used to produce diaryl trisubstituted triazines. In the first method, cyanuric chloride is first reacted with a 4-alkoxybenzylamine. The product of this reaction is then reacted with a resin-bound amine, such as 4-alkoxyb...
|
|
WO/2004/096782A1 |
The invention relates to a method for producing melamine from urea under high pressure, comprising a phase transition device (1) for transitioning a melamine melt into the gas phase. To this end, heat is fed to the phase transition devic...
|
|
WO2004026844A9 |
The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or bl...
|
|
WO/2004/093207A2 |
The invention relates to novel mixtures consisting of at least two substances, one substance being used as a matrix material and the other as a material which is capable of emission and contains at least one element having an atomic numb...
|
|
WO/2004/089927A1 |
Methods of inhibiting the cytokine or biological activity of Macrophage Migration Inhibitory Factor (MIF) comprising contacting MIF with a compound of formula (I) are provided. The invention also relates to methods of treating diseases o...
|
|
WO/2004/090017A1 |
Diamine compound containing specific triazine group, polyamic acid obtained by reacting the diamine compound and tetracarboxylic dianhydride, and liquid crystal alignment film obtained by coating and imidizing the polyamic acid. The liqu...
|
|
WO/2004/089917A2 |
The present invention is directed towards a process for resolving a racemic amino compound derived from dihydro- 1,3,5- triazines. The invention is also directed towards the enantiomers of amino derivatives of dihydro-1,3,5-triazines and...
|
|
WO/2004/089286A2 |
The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated tyrosine kinas...
|
|
WO/2004/085413A1 |
The invention relates to a method for the production of melamine from urea via high-pressure process, which accomplished at pressure of 6.0˜20.0MPa, temperature of 28°C˜480°C in one single body reactor setting multi-tower tray up and...
|
|
WO/2004/085381A1 |
A composition of matter is disclosed that comprises a compound of the formula AnR, wherein: A is (I), R1 is hydrocarbyl; m is 0 or 1; n is 1, 2 or 3; R is selected from the group consisting of: mono-, di-, and trivalent groups; mono-, di...
|
|
WO/2004/085412A2 |
Disclosed is the use of the compounds of formula wherein A is a radical of formula (1a) or (1b) R, R1 and R5 independently from each other are hydrogen; C1-C18alkyl; or C6-C12aryl; R2, R3 and R4 independently from each other are hydrogen...
|
|
WO/2004/082822A2 |
The invention includes methods for isolating crystalline Form I of 5-azacytidine substantially free of other forms, wherein 5-azacytidine is represented by the formula: The invention also includes pharmaceutical compositions comprising F...
|
|
WO/2004/078747A1 |
This invention relates to novel diaryl ureas of Formula (I), pharmaceutical compositions containing such compounds and the use of those compounds or compositions for treating hyperproliferative and angiogenesis disorders, as a sole age...
|
|
WO/2004/078746A2 |
This invention relates to novel diaryl ureas of formula (I), pharmaceutical compositions containing such compounds and the use of those compounds or compositions for treating hyper-proliferative and angiogenesis disorders, as a sole agen...
|
|
WO/2004/077885A2 |
Disclosed are electroluminescent devices that comprise organic layers that contain triazine compounds. The triazine compounds are suitable components of blue-emitting, durable, organo-electroluminescent layers. The electroluminescent dev...
|
|
WO/2004/074265A1 |
Method for crystallising a melamine melt to form melamine particles with a D90 of at most 2 mm by cooling a melamine melt to below the crystallisation temperature of the melamine, comprising the formation of a suspension of melamine part...
|
|
WO/2004/069814A1 |
The invention relates to an optically active compound of formula (I) or a salt thereof, wherein the various symbols are as defined in the description, to processes for their preparation, to compositions thereof, and to their use as herbi...
|
|
WO/2004/069823A1 |
The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell pr...
|
|
WO2004048320B1 |
Biguanide and dihydrotriazine derivatives, preferably substituted asymmetrical imidodicarbonimidic diamides derived from hydroxylamines, and compositions containing biguanide and dihydrotriazine derivatives are disclosed. In addition, me...
|
|
WO/2004/069790A2 |
This invention relates to a novel polymorph crystal form of the compound of formula (I), a process for its preparation and the use thereof.
|
|
WO/2004/069837A1 |
Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein.
|
|
WO/2004/065371A1 |
The invention relates to a method for the catalytic production of melamine by the decomposition of urea in particular on solid catalysts using a main and post reactor. A catalyst of low Lewis acidity is employed in the main reactor and i...
|
|
WO/2004/064797A1 |
The present invention relates to new compounds of formula (I), wherein R1, R2, R3, R4, R5, R6, R7, and R8 independently from each other are hydrogen; C1-C18alkyl; C2-C18alkenyl; C5-C7,cycloalkyl; C1-C6alkylene-C5- C7,cycloalkyl; R9 is hy...
|
|
WO/2004/054990A2 |
Disclosed is a method for producing alkoxycarbonylamino triazines of formula (I) by reacting diaminotriazines or triaminotriazines with cyclic carbonic acid esters and optional subordinate quantities of acyclic carbonic acid esters in th...
|
|
WO/2004/054989A1 |
An antibacterial characterized by containing as an active ingredient either a compound represented by the general formula (1) or a pharmacologically acceptable salt thereof.
|
|
WO/2004/052870A1 |
A compound of the formula (I) wherein each Z is the same or different and is formula (a) or -Y wherein each X is the same or different and is a multivalent aminyl group or diaminyl-terminated spacer; each Y is the same or different aminy...
|
|
WO/2004/050613A2 |
This invention provides 2-substituted-propenamide derivatives and their compositions for the treament of hepatitis B virus and/or hepatitis D virus.
|
|
WO/2004/046293A2 |
The present invention provides novel bis-triazinylaminostilbene amphoteric fluorescent whitening agents, comprising both individual components and mixtures thereof, a process for their preparation, intermediates useful for their preparti...
|
|
WO/2004/043938A1 |
1,3,5 (2H2,4H2,6H2) tripropanediamine N,N,N',N',N',N' hexamethyl is used to scavenge sulfur compounds from hydrocarbons. A novel method of making the triazine comprises autocondensing (CH3)2N CHCH2CH 2N=CH2.
|
|
WO/2004/041922A1 |
The present invention pertains to carbamate-melamine formaldehyde cross-linking agents of the formula (I), wherein X is selected from the group consisting of -COOR, -(CH2-O)l-H, -(CH2-O)l-R, -(CH2-O)k-CH2-N(X)-Q, and -(CH2-O)k-CH2-N(Y)-Q...
|
|
WO/2004/035199A1 |
Use of a compound of formula (I) wherein R1 and R2 are the same or different and are each optionally substituted alkyl or aryl; and R3 is a solid support optionally attached via a spacer; for the affinity binding of an immunoglobulin or ...
|
|
WO/2004/035551A2 |
The present invention is directed to novel fluorinated dye stabilizers having both high quenching efficiency and solubility in halogenated solvents. These dye stabilizers have shown a significantly effect on improving the dye fastness in...
|
|
WO/2004/032875A2 |
This invention provides a process for producing at least one tri-nitrogen containing heteroaryl-diamine derivatives, which are useful as pharmaceutical agents and components, particularly as IMPDH inhibitors, comprising reacting an isoth...
|
|
WO2002036578A9 |
The invention relates to triazines and the use thereof to inhibit lysophosphatidic acid acyltransferase beta (LPAAT- beta ) activity. The invention further relates to methods of treating cancer using said triazines. The invention also re...
|
|
WO/2004/020688A1 |
A method for producing a metal sulfide thin film, which comprises using a metal halide such as an iron halide (for example, FeCl3, FeI3, FeBr3, FeCl2, FeI2 or FeBr2) as a first material and a thioamide compound such as thioacetamide as a...
|
|
WO/2004/018453A1 |
Proline derivatives represented by the general formula (I) or salts thereof, useful as antibacterial drugs against multidrug-resistant bacteria: (I) (b) wherein A is a group derived from a 5- or 6-membered heterocycle which may be fused ...
|
|
WO/2004/016599A1 |
Process for the preparation of melamine, comprising a first mixing step in which at least two melamine-containing flows, origination from at least two different processes for the preparation of melamine, are brought into contact with eac...
|
|
WO/2004/016584A1 |
A fluorinated urethane compound represented by the general formula I[-NHC(=O)O-X1-Rf1-R1]m[-NHC(=O)O-(X2(-CH2Cl)O)p-R2]n (1) [wherein I is a group formed by removing an isocyanate group from a polyisocyanate compound; X1 is a divalent or...
|
|
WO/2004/013233A1 |
Anionic monoazo dyes of the formula (1) in which A represents a 1- or 2-naphthyl residue, which is substituted by a total of one or two sulphonic and/or carboxylic acid groups, R1 represents hydrogen or C1-C4alkyl, each D1 and D2, indepe...
|
|
WO/2004/013089A1 |
Fluorinated urethane compounds represented by the general formula (1) can impart high water- and oil-repellency: [Rf-A1-(X1(OH))-(Y1)a-OC(=O)NH-]m I [-NHC(=O)O-Y2]n [-NHC(=O)O-((ClCH2-)X2O)b-R1]k (1) wherein I is a group derived from a p...
|
|
WO/2004/013235A1 |
Reactive dyes of formula (I), wherein A is the radical of a monoazo, polyazo, metal complex azo, anthraquinone, phthalocyanine, formazan or dioxazine chromophore, Q1, and Q2 are each independently of the other hydrogen or unsubstituted o...
|
|
WO/2004/009561A1 |
Disclosed are 3-heterocyclyl substituted benzoic acid derivatives of general formula (I), in which the variables R1 to R8 and X have the meanings indicated in claim 1, and the use thereof as herbicides or for desiccating/defoliating plants.
|
|
WO/2004/005617A1 |
The present invention relates to a fluorescent whitening agent comprising a mixture of two symmetrically and one asymmetrically substituted triazinylaminostilbene disulphonic acids, novel asymmetrically substituted derivatives, a process...
|
|
WO/2004/002966A1 |
Treatment of the pyrolysis product of urea to melamine, in one or more expansion and cooling steps to separate the offgas and recover the melamine in solution/suspension, carried out by expanding the product under a liquid seal, to pre...
|
|
WO/2004/000819A1 |
The present invention therefore provides use of a compound of formula (I) and compositions for treating diseases associated with cysteine protease activity. The compounds are reversible inhibitors of cysteine proteases S, K, F, L and B. ...
|
|
WO/2004/000820A2 |
Compound having Formula (I): wherein (W) is a monocyclic ring having the structure are useful as modulators of kinase activity.
|
|
WO/2004/001018A2 |
The present invention provides compositions and methods relating to vacuolins and their uses. Vacuolins are small molecule agents that affect certain membrane fusion events involving intracellular compartments. The invention further prov...
|
|
WO/2003/101973A2 |
The invention relates to a compound of formula (I), refer to attached formula sheet, where: X is equal to NR5; R4 is equal to a C1-C12 alkyl group, aryl group, aralkyl group or cycloalkyl group. R1, R2, R3, R5 are equal to an H, alkyl, c...
|
|
WO/2003/101442A1 |
Novel PDF inhibitors and novel methods for their use are provided.
|
|
WO/2003/101444A1 |
Disclosed are novel inhibitors of Chk-1 and methods of using the same for therapy.
|
